Publications

  1. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer. Eur Urol. 2014 Aug 13. [Epub ahead of print]
    View PubMed
  2. Gupta, E Guthrie T, Tan W. Changing paradigms in management of metastatic castration resistant prostate cancer BMC Urology. 2014 July; 14:2490-14-55.
  3. Tan W, Moul, J. Androgen Supression in Castrate -Resistant Prostae Cancer. Personalized Medicine in Oncology. June 2014; 3(4):212-219. Epub 2014 Jun
  4. Ames SC, Pokorny SB, Schroeder DR, Tan W, Werch CE. Integrated smoking cessation and binge drinking intervention for young adults: a pilot efficacy trial. Addict Behav. 2014 May; 39(5):848-53. Epub 2014 Feb 12.
    View PubMed
  5. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):477-83. Epub 2013 Jul 26.
    View PubMed
  6. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol. 2013 Oct; 24(10):2548-54. Epub 2013 Jun 24.
    View PubMed
  7. Tan WW. 14 Skin lesions caused by Cancer Chemotherapy. Medscape: reference. 09/04/2013(9):1-16.
  8. von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW, Copland JA. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013 May 1; 19(9):2368-80. Epub 2013 Apr 30.
    View PubMed
  9. Tan WW, Heckman MG, Vishnu P, Crook JE, Younkin LH, Covil EG, Ferman TJ, Graff-Radford NR, Younkin SG, Smallridge RC, Wehle MJ, Buskirk SJ. Effect of leuprolide on serum amyloid-beta peptide levels and memory in patients with prostate cancer with biochemical recurrence. Urology. 2013 Jan; 81(1):150-4.
    View PubMed
  10. Tan W. Reply. Urology. 2013 Jan; 81(1):154.
    View PubMed
  11. Valery JR, Tan W, Cortese C. Renal leiomyosarcoma: a diagnostic challenge. Case Rep Oncol Med. 2013; 2013:459282. Epub 2013 Oct 29
    View PubMed
  12. Gardner FP, Tan WW. Ataxia in a patient with urothelial carcinoma: Pathologic confirmation, recovery, and improved survival. Clin. adv. hematol. oncol. 2013; 11(7):465-7.
  13. Ahmad A, Wu K, Tan WW. Renal Cell Carcinoma with Skin metastasis: A Case Report and Literature Review. Cancer and Clinical Oncology. 01/2013; 2(1):1-7.
  14. Andhavaradrapu S, Tan WW. Practical insights and challenges in the rational use of targeted agents in metastatic clear cell renal carcinoma. Cancer and Clinical Oncology. 2012 May; 125(1361):102-104 Epub 2012.
  15. Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer. 2012 Apr; 12(2):81-6.
    View PubMed
  16. Finn L, Tan W. Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents. ISRN Oncol. 2012; 2012:478607. Epub 2012 Jun 3.
    View PubMed
  17. Ahmad A, Tan W. Atypical Presentation of Prostate Cancer and workup of an adenocarcinoma of Unknown primary. World J Urol. 2012(3(4)):187-190.
  18. Ahmad A, Tan WW. Castrate Resistant Metastatic Prostate Cancer: Options for a Patient in 2012. Open Journal Urology. 2012; 2:210-215 Epub 2012 Oct.
  19. Andhavarapu S, Tan WW. Medical image. papules of unknown aetiology. Disseminated Curvularia. N Z Med J. 2012; 125(1361):102-4. Epub 2012 Sep 07.
    View PubMed
  20. Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD Jr, Crook JE, Williams CR, Werch CE, Clark MM, Rummans TA. A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. Psychooncology. 2011 Apr; 20(4):435-40. Epub 2010 May 24.
    View PubMed
  21. Tzou K, Tan WW, Buskirk S. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy. Expert Rev Anticancer Ther. 2011 Jan; 11(1):125-36.
    View PubMed
  22. Ames SC, Parker AS, Crook JE, Diehl NN, Tan WW, Williams CR, Ames GE. Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma. J Psychosoc Oncol. 2011; 29(6):593-605.
    View PubMed
  23. Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther. 2011; 4:97-113. Epub 2011 Jul 11.
    View PubMed
  24. Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2010 Mar; 21(3):493-7. Epub 2009 Jul 22.
    View PubMed
  25. Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA. Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist. 2010; 15(10):1043-9. Epub 2010 Oct 07.
    View PubMed
  26. Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther. 2010; 3:39-51. Epub 2010 Jun 24.
    View PubMed
  27. Hines S, Tan WW, Moreno A, Roy V, Vallow L, Mclaughlin S, Perez, E. A practical Clinical appraoch to Adjuvant Therapy in Breast Cancer- An update. US Oncological Review. 2009; 5 (1):49-53.
  28. Tan W, Hillman D, Salim M, Northfelt D, Anderson D, Stella P, Niedringhaus R, Bernath Jr. A, Gamini S, Palmieri F, Perez E. N0332 Phase 2 Trial of Weekly Irinotecan Hydrochloride and Docetaxel in Refractory Metastatic Breast Cancer: A North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2009:(Published On-Line).
    View PubMed
  29. Moss JE, Tan WW, Menke DM, Johnson MM. Multiple pulmonary nodules in an asymptomatic man. The Journal of Medicine. 2009; 2(4):205-10.
  30. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7940-6.
    View PubMed
  31. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008 Sep; 19(9):1561-5. Epub 2008 Jun 05.
    View PubMed
  32. Coe SG, Tan WW, Fox TP. Cushing's syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life. J Gen Intern Med. 2008 Jun; 23(6):875-8. Epub 2008 Apr 02.
    View PubMed
  33. Hines SL, Tan W, Larson JM, Thompson KM, Jorn HK, Files JA. A practical approach to guide clinicians in the evaluation of male patients with breast masses. Geriatrics. 2008 Jun; 63(6):19-24.
    View PubMed
  34. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008; 8:132. Epub 2008 May 11.
    View PubMed
  35. Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD Jr, Heckman MG, Crook JE, Clark MM, Rummans TA, Werch CE. Quality of life of men with biochemical recurrence of prostate cancer. J Psychosoc Oncol. 2008; 26(2):17-34.
    View PubMed
  36. Tan W. [Promising new treatment options for metastatic androgen-independent prostate cancer]. Actas Urol Esp. 2007 Jun; 31(6):680-5.
    View PubMed
  37. Hines SL, Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007 Mar; 82(3):297-300.
    View PubMed
  38. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W, North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007 Feb; 69(2):289-94.
    View PubMed
  39. Lee S, Desai KK, Iczkowski KA, Newcomer RG, Wu KJ, Zhao YG, Tan WW, Roycik MD, Sang QX. Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res. 2006 Sep; 16(9):750-8.
    View PubMed
  40. Tan WW. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control. 2006 Jul; 13(3):194-8.
    View PubMed
  41. Hughes CL, Tan WW, Ferrone M. Sorafenib for the treatment of renal cell carcinoma. J Pharm Technol. 2006; 22(5):281-8.
    View PubMed
  42. Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer. 2005 Sep; 4(2):138-41.
    View PubMed
  43. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005 Jun; 23(3):257-61.
    View PubMed
  44. Tan M, Tan W. Polypharmacy in the Elders.(CME article) Federal Practitioner. 2005; 22(11):76-88.
  45. Baweja M, Tan W. Bone metastases from Prostate cancer: Known and Novel targets for palliation. Palliative and Supportive Cancer care Journal. 2005; 1(2):47-58.
    View PubMed
  46. Mincey BA, Tan W. The management of bone loss in patients with breast or prostate cancer. Support Cancer Therapy. 2004; 1(3):1-7.
    View PubMed
  47. Tan M, Tan W. Osteoporosis in prostate cancer(CME Article). Federal Practitioner. 2004; 21(12):72-9.
  48. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 2003 Mar 15; 97(6):1442-6.
    View PubMed
  49. Tan WW, Walsh T. Ocular toxicity secondary to paclitaxel in two lung cancer patients. Medical & Pediatric Oncology. 1998 Sep; 31(3):177.
    View PubMed
  50. Tan W, Herzlich BC, Funaro R, Koutelos K, Pagala M, Amaladevi B, Grob D. Rhabdomyolysis and myoglobinuric acute renal failure associated with classic heat stroke. South Med J. 1995 Oct; 88(10):1065-8.
    View PubMed
  51. Tan W, Chapnick E, Abter EIM, et al. Paromomycin associated pancreatitis in HIV related cryptosoridiosis. Ann Pharmacother. 1995; 29:22-3.
    View PubMed
  52. Tan W, Schiano TD, Moss D, Herzlich BC. Hepatic artery aneurysm associated with acute gastroenteritis: successful treatment after intraperitoneal rupture. South Med J. 1994 Aug; 87(8):831-2.
    View PubMed
  53. Tan W, Chua M. Hemolytic anemia in SLE. The Philippine Journal of Pediatrics. 1989; 38(4):255-8.